Patients with Philadelphia chromosome–positive acute lymphoblastic or chronic myeloid leukemias in lymphoid blast phase may have longer event-free and overall survival with a combination of inotuzumab ozogamicin and bosutinib than with standard chemotherapy combined with a targeted agent, investigators in a phase 1/2 study reported.